why choose us

First received: December 8, 2022

Clinical Trial: Evaluate Bioequivalence of Burotam (1/1 g/Vial)

Study Status: Active, not recruiting

Recruit Status: Active, not recruiting

Condition: A Randomized, Single-dose, Two-way Crossover Study to Evaluate Bioequivalence of Two Formulations of

Study Type: Interventional


Official Title: A Randomized, Single-dose, Two-way Crossover Study to Evaluate Bioequivalence of Two Formulations of Cefoperazone Sodium and Sulbactam Sodium Combination (1/1 g/Vial) After Intravenous Infusion of 1 g

Brief Summary: A randomized, single-dose, two-way crossover study to evaluate bioequivalence of two formulations of cefoperazone sodium and sulbactam sodium combination (1/1 g/vial) after intravenous infusion of 1 g cefoperazone sodium and 1 g sulbactam sodium in healthy volunteers under fasting conditions

Read more